Metformin Actavis

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metformin Actavis (Metformin Hydrochloride)

Q: What is Metformin Actavis used for?

Metformin Actavis is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It is used alone or in combination with diet, exercise, and other antihyperglycemic agents to achieve target glycemic levels.

Q: How does metformin work?

Metformin lowers blood sugar by inhibiting hepatic glucose production, reducing intestinal glucose absorption, and enhancing peripheral insulin sensitivity through activation of AMP‑activated protein kinase (AMPK). These mechanisms lower circulating glucose without increasing insulin secretion.

Q: What is the usual dose of Metformin Actavis?

The dosage of Metformin Actavis is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose and titration schedule.

Q: Is Metformin Actavis safe during pregnancy or breastfeeding?

Safety data for metformin in pregnancy are limited, and it is generally used only when the potential benefit outweighs the risk. Metformin is excreted in breast milk; therefore, breastfeeding mothers should discuss potential risks and alternatives with their healthcare provider.

Q: How do I order Metformin Actavis from GNH India?

To place an order, submit an enquiry on the Metformin Actavis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Metformin Actavis compare with other antidiabetic drugs?

Compared with sulfonylureas, metformin does not stimulate insulin secretion, reducing the risk of hypoglycemia. It also promotes modest weight loss, whereas sulfonylureas can cause weight gain. Metformin is often preferred as first‑line therapy for type 2 diabetes because of its efficacy, safety profile, and cardiovascular benefits.

Q: How should Metformin Actavis be stored and handled?

Metformin Actavis should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

Q: How is Metformin Actavis administered?

Metformin Actavis is taken orally, usually with meals to lessen gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with Metformin Actavis?

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or in those consuming excessive alcohol. Other serious concerns include vitamin B12 deficiency and severe hypoglycemia when combined with insulin or sulfonylureas.

Q: Who should not use Metformin Actavis?

Metformin Actavis is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and in those with known hypersensitivity to metformin or other biguanides. Caution is also advised for patients with significant liver disease.

Metformin, the active ingredient in Metformin Actavis, is a biguanide presented as an oral dosage form for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus. It is indicated as part of a comprehensive diabetes management program that includes diet, exercise and other antihyperglycemic agents when appropriate.

GNH India supplies Metformin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Manufacturer / TM Owner

Actavis Group Ptc Ehf.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformin Actavis is used in the management of disorders related to impaired glucose metabolism, primarily type 2 diabetes mellitus.

Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose levels.
Type 2 diabetes mellitus (adjunct to diet and exercise): enhances overall glycemic control when lifestyle measures alone are insufficient.
Type 2 diabetes mellitus (combination therapy): provides additive glucose‑lowering effect when used with other antihyperglycemic agents such as sulfonylureas or insulin.

How It Works

Metformin reduces hepatic gluconeogenesis, decreases intestinal absorption of glucose, and improves peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). These actions collectively lower circulating glucose concentrations without stimulating insulin secretion, thereby aiding long‑term glycemic control in patients with type 2 diabetes.

Side Effects

Metformin may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects

Nausea: mild to moderate discomfort often occurring after the first doses.
Diarrhea: loose stools that may improve with continued therapy.
Abdominal discomfort: cramping or bloating.
Metallic taste: transient alteration in taste perception.
Weight loss: modest reduction in body weight.
Vitamin B12 deficiency: gradual decrease detectable with long‑term use.

Serious or Rare Side Effects

Lactic acidosis: a rare but potentially fatal accumulation of lactate.
Severe hypoglycemia: usually when combined with insulin or sulfonylureas.
Hepatic dysfunction: abnormal liver enzymes indicating liver injury.
Skin rash or hypersensitivity: including Stevens‑Johnson syndrome.
Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
Renal impairment worsening: decline in kidney function due to accumulation of the drug.

Precautions & Warnings

Before initiating Metformin Actavis, several safety considerations should be reviewed.

Renal function assessment: evaluate creatinine clearance to ensure adequate excretion.
Hepatic function monitoring: avoid use in patients with significant liver disease.
Contraindication in severe renal impairment: do not use if eGFR <30 mL/min/1.73 m².
Alcohol consumption: limit intake to reduce risk of lactic acidosis.
Elderly dosing: consider lower starting dose and titrate cautiously.
Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Metformin Actavis can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
Cimetidine: can raise metformin plasma concentrations.
Trimethoprim: may reduce renal clearance of metformin.

Moderate Interactions (Monitor Closely)

Beta‑blockers: can mask hypoglycemia symptoms.
Diuretics (especially thiazides): may affect renal function and electrolyte balance.
ACE inhibitors or ARBs: monitor renal function and potassium levels when used together.

Frequently Asked Questions

Metformin Actavis is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It is used alone or in combination with diet, exercise, and other antihyperglycemic agents to achieve target glycemic levels.

Metformin lowers blood sugar by inhibiting hepatic glucose production, reducing intestinal glucose absorption, and enhancing peripheral insulin sensitivity through activation of AMP‑activated protein kinase (AMPK). These mechanisms lower circulating glucose without increasing insulin secretion.

The dosage of Metformin Actavis is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose and titration schedule.

Safety data for metformin in pregnancy are limited, and it is generally used only when the potential benefit outweighs the risk. Metformin is excreted in breast milk; therefore, breastfeeding mothers should discuss potential risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the Metformin Actavis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sulfonylureas, metformin does not stimulate insulin secretion, reducing the risk of hypoglycemia. It also promotes modest weight loss, whereas sulfonylureas can cause weight gain. Metformin is often preferred as first‑line therapy for type 2 diabetes because of its efficacy, safety profile, and cardiovascular benefits.

Metformin Actavis should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and heat. Keep the product out of reach of children and avoid exposure to direct sunlight.

Metformin Actavis is taken orally, usually with meals to lessen gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, or in those consuming excessive alcohol. Other serious concerns include vitamin B12 deficiency and severe hypoglycemia when combined with insulin or sulfonylureas.

Metformin Actavis is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and in those with known hypersensitivity to metformin or other biguanides. Caution is also advised for patients with significant liver disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 05 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.